TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Short Interest Update
TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Short Interest Update
TC Biopharm (Holdings) Plc (NASDAQ:TCBP – Get Rating) was the recipient of a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 8,900 shares, a decrease of 88.0% from the February 28th total of 74,100 shares. Based on an average trading volume of 1,130,000 shares, the days-to-cover ratio is presently 0.0 days.
TC 生物製藥 (控股) 有限公司 (NASDAQ: TCBP — 獲得評級) 是在三月份短期利益大幅下降的接收者.截至 3 月 15 日，短期利息總額為 8,900 股，較二月二十八日的 74,100 股股份減少 88.0%。根據 1,130,000 股的平均交易量計算，日數佔覆蓋率目前為 0.0 天。
TC Biopharm Trading Down 6.6 %
TC 生物製藥成交易下跌 6.6%
NASDAQ:TCBP traded down $0.12 during trading hours on Tuesday, reaching $1.64. 228,787 shares of the stock were exchanged, compared to its average volume of 1,248,478. The firm has a 50 day simple moving average of $4.66 and a 200-day simple moving average of $7.17. TC Biopharm has a 52 week low of $1.46 and a 52 week high of $106.50.
納斯達克：TCBP 週二交易時間內下跌 0.12 美元，達到 1.64 美元。228,787 股的股票被交換，相比其平均交易量為 1,248,478。該公司的 50 天簡單移動平均線為 4.66 美元，以及 200 天的簡單移動平均線 7.17 美元。TC 生物製藥有 52 周低點為 1.46 美元，52 周高點為 106.50 美元。
Hedge Funds Weigh In On TC Biopharm
對沖基金權衡 TC 生物製藥
Several large investors have recently added to or reduced their stakes in TCBP. Legal & General Group Plc bought a new stake in TC Biopharm during the second quarter valued at $76,000. Renaissance Technologies LLC lifted its holdings in TC Biopharm by 581.7% in the third quarter. Renaissance Technologies LLC now owns 146,400 shares of the company's stock worth $41,000 after acquiring an additional 124,925 shares during the last quarter. Virtu Financial LLC lifted its holdings in TC Biopharm by 454.0% in the third quarter. Virtu Financial LLC now owns 130,005 shares of the company's stock worth $35,000 after acquiring an additional 106,539 shares during the last quarter. KCL Capital L.P. acquired a new position in TC Biopharm in the second quarter valued at approximately $37,000. Finally, Armistice Capital LLC bought a new position in shares of TC Biopharm during the fourth quarter valued at approximately $318,000. 66.72% of the stock is currently owned by institutional investors.
一些大型投資者最近增加或減少了他們在 TCBP 的股份。法律與通用集團有限公司在第二季度購買了 TC 生物製藥的新股份，價值為 76,000 美元。文藝復興科技有限責任公司在第三季度取消了其對 TC 生物製藥的持有量 581.7％。文藝復興科技有限責任公司現在擁有該公司股票的 146,400 股價值 41,000 美元在上個季度額外購買 124,925 股後。唯圖金融有限責任公司在第三季度將其對 TC 生物製藥的持有量提高了 454.0%。維圖金融有限責任公司現在擁有該公司股票的 130,005 股，價值 35,000 美元，在上一季度額外獲得 106,539 股股票後。KCL 資本有限公司於第二季收購 TC 生物製藥的新職位，價值約為 37,000 美元。最後，停戰資本有限責任公司在第四季度買入 TC 生物藥業股份的新頭寸，價值約為 318,000 美元。66.72％ 的股票目前由機構投資者擁有。
Analysts Set New Price Targets
分析師設定新的價格目標
Separately, HC Wainwright began coverage on shares of TC Biopharm in a research note on Thursday, January 26th. They issued a "buy" rating and a $9.00 target price on the stock.
另外，HC 溫賴特於 1 月 26 日（星期四）在一份研究報告中開始對 TC 生物製藥的股份進行報導。他們發布了「買入」評級和 9.00 美元的股票目標價。
About TC Biopharm
關於 TC 生物製藥
(Get Rating)
(取得評分)
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19.
TC 生物醫藥（控股）有限公司是一家臨床階段生物製藥公司，致力於開發基於同種異體伽瑪三角量 T 細胞平台的免疫治療產品。其產品管線包括 OMN免疫/Om免疫性，一種用於治療急性髓細胞白血病的未經修飾的細胞療法；以及用於治療 COVID-19 的未經修飾的細胞療法 ImmunisTim。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on TC Biopharm (TCBP)
- Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
- Roku And The 20% Rally That's About To Start
- It's Rally-On! For PVH Corp. But How High Can It Go?
- Boring is Beautiful, Illinois Tool Works Stock Fits the Bill
- Don't Be Fooled by These 3 Value Traps
- 索取有關 TC 生物醫藥研究報告的免費副本
- 沃爾格林靴子聯盟：藍籌，高收益周轉故事
- Roku 和即將開始的 20％ 拉力賽
- 這是拉力上！對於 PVH 公司，但它能走多高？
- 無聊是美麗的伊利諾伊州工具工程股票符合條例草案
- 不要被這 3 個價值陷阱所迷惑
Receive News & Ratings for TC Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TC Biopharm and related companies with MarketBeat.com's FREE daily email newsletter.
接收 TC 生物製藥日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 TC 生物製藥及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。